Adjuvant zoledronic acid was associated with low incidence of ONJ and did not affect oral quality of life.
The prior, industry-supported AZURE trial (N Engl J Med 2011 Oct 13; 365:1396) demonstrated that the bisphosphonate zoledronic acid (ZA), in combination with standard adjuvant systemic therapy, had no effect on disease-free survival in the overall study population of patients with stage II or III breast cancer, although it significantly reduced the risk for recurrence and death in the subset of postmenopausal patients. Bisphosphonate therapy has also been associated with osteonecrosis of the jaw (ONJ), characterized by exposed bone, most commonly in the mandible, as well as by loose teeth, draining fistulas, secondary infections, and localized pain.
Now, investigators have evaluated the incidence and impact of ONJ in 3360 women in the AZURE …
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)